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freshly resected breast cancer specimen
staining
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Abstract
Background: Re-excision rates following breast conserving surgery (BCS) remain as high as ~ 35%, with positive
margins detected during follow-up histopathology. Additional breast cancer resection surgery is not only taxing on
the patient and health care system, but also delays adjuvant therapies, increasing morbidity and reducing the
likelihood of a positive outcome. The ability to precisely resect and visualize tumor margins in real time within the
surgical theater would greatly benefit patients, surgeons and the health care system. Current tumor margin
assessment technologies utilized during BCS involve relatively lengthy and labor-intensive protocols, which impede
the surgical work flow.
Methods: In previous work, we have developed and validated a fluorescence imaging method termed dual probe
difference specimen imaging (DDSI) to accurately detect benign and malignant tissue with direct correlation to the
targeted biomarker expression levels intraoperatively. The DDSI method is currently on par with touch prep
cytology in execution time (~ 15-min). In this study, the main goal was to shorten the DDSI protocol by decreasing
tissue blocking and washing times to optimize the DDSI protocol to < 10-min whilst maintaining robust benign
and malignant tissue differentiation.
Results: We evaluated the utility of the shortened DDSI staining methodology using xenografts grown from cell
lines with varied epidermal growth factor receptor (EGFR) expression levels, comparing accuracy through receiver
operator characteristic (ROC) curve analyses across varied tissue blocking and washing times. An optimized 8-min
DDSI methodology was developed for future clinical translation.
Conclusions: Successful completion of this work resulted in substantial shortening of the DDSI methodology for
use in the operating room, that provided robust, highly receptor specific, sensitive diagnostic capabilities between
benign and malignant tissues.
Keywords: Dual probe difference specimen imaging, Breast conserving surgery, Tumor margin assessment,
Fluorescence guided surgery, Paired agent imaging
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Background
With more than 284,000 expected new breast cancer
diagnoses in 2021 alone, breast cancer is the second
leading cause of cancer related deaths for women in the
United States (US) making early, and precise, treatment
imperative [1]. Currently, the standard of care for the
treatment of early stage breast cancer is breast conserving surgery (BCS) followed by adjuvant therapy [2, 3].
The success of BCS, however, is reliant upon negative or
clear margins, with positive margin status thought to be
a primary indicator of local breast cancer recurrence [4].
BCS cases with positive margin status as determined by
histopathology necessitate follow-up surgery. Standard
of care BCS procedures result in positive margins in up
to 35% of patients [5], leading to re-excision, where
higher positive margin rates are seen at centers where
larger normal tissue borders around tumor are required.
Additionally, in many BCS patients with adequate tumor
margins, negative margins are achieved at the expense of
excessive resection of healthy breast tissue with lumpectomy volumes up to 2.5x greater than the necessary resection volume [6]. Not only does follow up surgery
delay adjuvant therapy, but it also leads to increased patient stress giving way to an increase in patient morbidity and mortality rates [7–11]. The implementation of
intraoperative margin detection methodologies based on
pathology techniques including touch prep cytology [12]
and frozen section analysis (FSA) [13] have been successful in reducing re-excision rates. However, these
aforementioned procedures not only increase surgical
time and are dependent upon the presence of a pathologist, but they have also been found to contain significant
variation in their sensitivity and specificity between studies [14, 15]. Consequently, the majority of US hospitals
have not adopted these pathology based techniques for
intraoperative margin assessment during BCS, thus warranting a modality that is able to decrease re-excision
rates in a rapid platform within the operating room
(OR) [16].
Fluorescence guided surgery (FGS) is an optical imaging modality that has become an attractive tool for intraoperative margin assessment due to its real time
imaging capabilities. Fluorescent contrast agents for intraoperative cancer margin assessment are under clinical
trial for colorectal, pancreatic, bladder, brain, prostate,
head and neck, sarcoma, breast, skin, lung, cervical,
ovarian, esophageal and renal cancers [17–19]. However,
the path to clinical translation is long and expensive as
all ongoing clinical trials apply the novel fluorescent
contrast agent to the patient, necessitating extensive
safety testing. In the case of BCS and other cancer resections, the diseased tissue is removed from the patient
and thus could be stained outside of the body, not requiring patient contact. Technologies that are solely
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executed on the excised patient samples have a much
shorter path to Food and Drug Administration (FDA)
approval, since safety testing is not required. While other
detection methods have been evaluated for resected specimen staining [20–24], this work is focused on the utility of fluorescence. Given the gaining popularity of FGS
and the increase use of “back-table” or ex vivo fluorescence evaluation of resected samples that contain fluorescent contrast administered in vivo, “back-table” FGS
systems are currently under commercial development
[25, 26]. While all fluorescent contrast will be applied to
the resected specimens for our proposed studies, these
“back-table” systems are an attractive path to clinical
translation for application of our fluorescence based
dual-probe difference specimen imaging (DDSI) method
for ex vivo staining and biomarker quantification.
In previous work, a robust staining protocol was developed that utilized a dual-probe staining cocktail containing a biomarker targeted probe and matched untargeted
probe, which were labeled with spectrally-distinct fluorophores to accurately differentiate between benign and
malignant tissues. This novel DDSI methodology proved
to be both molecularly specific (89%) and extremely sensitive (97%) for differentiation between benign and malignant murine tissues [27]. Furthermore, DDSI has been
validated in several cell lines with varying expression
levels of epidermal growth factor receptor (EGFR) and
human epidermal growth factor receptor 2 (HER2), confirming the receptor specific diagnostic capabilities of
the DDSI methodology [27, 28]. However, the validated
DDSI protocol required a total of 16 min for tissue processing time to provide diagnostic information. While
this time frame is on par with touch prep cytology [29],
it is still rather lengthy and untenable if iterative resection and DDSI is required to accurately quantify margin
status. The longest steps in our previously published
DDSI protocol were the pre-staining blocking step and
the post-staining washing step. Thus, herein we examined the diagnostic accuracy of the DDSI method upon
shortening both these steps. Receiver operator characteristic (ROC) curve analysis and calculated area under the
curve (AUC) values were used as the metric of diagnostic performance and as a comparison to the previously
optimized protocol. Ultimately optimization of a clinically relevant DDSI method would enable rapid margin
assessment, while preserving tissue integrity for gold
standard histopathology, paving the path for ready clinical translation.

Methods
Fluorophores & antibodies

The N-Hydroxysuccinimide (NHS) ester form of Alexa
Fluor 647 (AF647, Thermo Fisher Scientific, Waltham,
MA) and Cy3B (GE Healthcare Life Sciences, Little
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Chalfont, UK) were purchased and solubilized in anhydrous dimethyl sulfoxide (DMSO) at 10 mM for antibody
conjugation. For the targeted probe, Cetuximab (Erbitux,
Eli Lilly and Company, Branchburg, NJ, molecular weight
[MW] = 152 kDa) was used and for the untargeted probe,
Donkey anti-Rabbit IgG (DkRb, Jackson ImmunoResearch, West Grove, PA, MW = 150 kDa) was used.
Cell lines

The human epidermoid carcinoma cell line A431, human pancreatic adenocarcinoma cell line AsPC-1, and
rat gliosarcoma cell line 9L were cultured in DMEM 1x
(Gibco/Thermo Fisher Scientific) with 10% fetal bovine
serum (FBS, Seradigm, Sanborn NY) and 1% PenicillinStreptomycin-Glutamine (Thermo Fisher Scientific). All
cell lines were a generous gift from Dr. Kimberley Samkoe (Dartmouth College, Hanover, NH). All cell lines
were grown to ~ 90% confluence prior to use for xenograft implantation.
Antibody-Fluorophore conjugation

As previously described [27], the targeted Cetuximab
probe was conjugated to AF647, and the untargeted Dkanti-Rb IgG probe was conjugated to Cy3B. The antibody
conjugation reactions to their respective fluorophores are
explained briefly as follows. The antibodies were buffer exchanged into 1x PBS at pH 8.0. Then, 1.5 μl of 10 mM
AF647 in anhydrous DMSO was added to 220 μL of
Cetuximab and 1 μL of 10 mM Cy3B, in anhydrous
DMSO, was added to 220 μL of DkRb. The mixtures were
vortex for 2 h at room temperature, protected from light.
Prior to purification, the antibody-fluorophore mixtures
were concentrated in 10 kDa molecular weight cut off
(MWCO) spin filters, then purified through a 6 kDa
MWCO desalting column using fast protein liquid chromatography (FPLC, Bio-Rad Laboratories, Hercules, CA).
Absorbance spectroscopy (SpectraMax M5, Molecular
Devices, San Jose, CA) was used to quantify the antibody
to fluorophore conjugation ratio by measuring the antibody absorbance at 280 nm (Cetuximab and DkRb extinction coefficient (ε) = 210,000 M− 1 cm− 1), Cy3B absorbance
at 560 nm (Cy3B ε = 130,000 M− 1 cm− 1), and AF647 absorbance at 650 nm (AF647 ε = 270,000 M− 1 cm− 1). DDSI
staining solution was composed of a mixture of
Cetuximab-AF647 and DkRb-Cy3B containing 1x PBS
pH 7.4, 0.1% Tween 20 and 1% Bovine Serum Albumin
(BSA) at a final concentration 200 nM of each antibody
measured by protein concentration.
Flow Cytometry

Cells were trypsinized, counted, and fixed in 4% paraformaldehyde (PFA) for 10 min. A 3 min permeabilized step
(0.5% Triton-X) was followed by 2 × 5 min washes in
phosphate buffered saline (PBS) and then 2 × 106 cells/
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cell line were blocked for 15 min with 5% FBS. Without
removing the blocking buffer, the cells were incubated
with 5 μg/ml Cetuximab directly conjugated to AF647
(1:1.7 antibody to fluorophore conjugation ratio). Cells
were washed 1 × 5 min with PBS + 0.1% Tween 20,
followed by 2 × 5 min PBS washes, and finally resuspended in fresh PBS prior to analysis on a Becton Dickinson LSR Fortessa (Becton, Dickinson and Company,
Franklin Lakes, NJ). The flow cytometer was configured
with a 640–1 (670/30) Cy5 channel to detect AF647. A
minimum of 1 × 105 cells were counted for each sample.
To quantify EGFR receptor number, Quantum™ Alexa
Fluor® 647 molecules of equivalent soluble fluorophore
(MESF) beads (Bangs Laboratories, Inc., Fishers, IN)
were quantified prior to the cellular samples.
Mice, Tumor Implantation & Growth

Female athymic nude mice (32–38 day old, Homozygous
490, Charles River Laboratories, Wilmington, MA) weighing 19–21 g were used to grow xenografts of each cell line.
All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) at Oregon Health
and Science University (OHSU). All studies were
performed in accordance with these approved guidelines
and regulations, which fulfill the ARRIVE guidelines for
pre-clinical animal studies. Prior to implantation, mice
were anesthetized using 200 μL of a 100 mg/kg Ketamine
(Hospira Inc., Lake Forest IL) and 10 mg/kg Xylazine
(AnaSed, Shenandoah, IA) solution administered by intraperitoneal (IP) injection. The toe pinch method was used
to assess depth of anesthesia.
For A431 and AsPC-1 tumor implantation, the lower
peritoneal area was prepared, in a sterile field using
povidine-iodine (Purdue Products, Stamford, CT). Along
the lateral side of each inferior nipple a small incision
(3–5 mm) was made, followed by mammary adipose extraction though the incision using forceps. 200 μL of cell
suspension (1 × 106 cells) was injected into the mammary adipose. The mammary adipose was then inserted
back into the incision site and the incision was sealed
with Vetbond™ (3 M, St. Paul, MN). For 9L xenografts, a
200 μL injection of a 1:1 cell suspension (1 × 106 cells) to
Matrigel (Corning, Corning, NY) was subcutaneously
injected into both hind flanks. The mice were monitored
daily for 5–7 days following the procedure to ensure
healing of the surgical site and then weekly for tumor
growth and overall health.
Tumors were grown until they reached a maximum
size of 1.5 cm3, which occurred in 2–3 weeks for both
A431 and 9L xenografts, and 4–5 weeks for AsPC-1 xenografts. Tumors were resected and bisected resulting in
n = 6 tumor samples per blocking condition. For every
tumor sample, a corresponding adipose sample was
resected as the representative benign control tissue. Six
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blocking conditions were tested in both the A431 and
AsPC-1 tumors types and three blocking conditions
were tested in the 9L tumor type, where in total n = 18
A431, n = 18 AsPC-1 and n = 9 9L tumors were used.
Tumor resection & DDSI staining

Carbon dioxide (CO2) asphyxiation followed by cervical
dislocation was used to euthanize all mice prior to
tumor excision, a method consistent with the recommendations by the panel on euthanasia of the American
Veterinary Medical Association. Each replicate of tumor
and adipose tissue was blocked, stained, and washed together in a single Eppendorf tube. Six blocking conditions were tested for each xenograft type: no blocking,
2% BSA for 10 min, 5% BSA for 1 min, 5% BSA for 2
min, 10% BSA for 1 min and 10% BSA for 2 min. All
BSA solutions were in 1x PBS at pH 7.4. The previously
optimized DDSI staining protocol was used [27], briefly
explained as follows: 1 mL of 200 nM CetuximabAF647 + 200 nM DkRb-Cy3B in 1x PBS, pH 7.4 containing 1% BSA and 0.1% Tween20 was incubated with the
tumor and adipose tissues simultaneously for 1 min. The
tissue samples were imaged immediately after staining
on a glass slide with the tumor cut face oriented towards
the light source and camera. Images were collected after
1 min washes in 50 mL of PBS containing 0.1% Tween20 for up to 5 min.
DDSI macroscopic imaging

Color and fluorescence images of the tumor and adipose
tissues were collected using a previously described
custom-built wide field fluorescence imaging system
[30], detailed briefly as follows. A QImaging EXi Blue
monochrome camera (Surrey, British Columbia, CA)
with a removable Bayer filter and a PhotoFluor II light
source (89 North, Burlington, VT) made up the macroscopic fluorescence imaging system. For excitation of
Cy3B and AF647, the broad band light source was filtered using a 545 ± 12.5 nm or 620 ± 30 nm bandpass excitation filter, respectively. For fluorescence detection of
Cy3B or AF647, a 605 ± 35 nm or a 700 ± 37.5 nm bandpass emission filter was placed in front of the camera,
respectively. All filters were obtained from Chroma
Technology (Bellows Falls, VT). An aliquot of the staining solution was placed in a covered optical well plate
(Greiner Bio-One, Monroe, NC) and imaged with each
set of tissues for image calibration.
DDSI image processing

Custom written MatLab code (MathWorks, Natick, MA)
was used to generate DDSI maps from the collected targeted and untargeted fluorescence images, described
briefly as follows. Average median background signal was
calculated from selected regions of interest (ROI) not
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containing any tissue and subtracted from the entire
image. To normalize intensity between fluorescence channels, a region of interest was also selected from the DDSI
staining solution calibration sample images in which an
average intensity value was calculated. Each pixel value in
each fluorescence image was divided by the average intensity value of the ROI from the respective imaging channel’s DDSI staining solution image. Manual masks were
created by the user to identify tissue sample ROIs containing tumor or normal tissues based on the white light images, which were then applied to each fluorescence image.
DDSI images were calculated as

I DDSI ¼ I Targeted −I Untargeted =I Untargeted
where I = mean signal intensity.
IHC Staining & Microscopy

Upon completion of the DDSI protocol, each tumor and
adipose tissue replicate was flash frozen in optimal cutting temperature (OCT, Fisher HealthCare, Houston,
TX) compound to maintain the tissue orientation from
the macroscopic tissue imaging studies. All OCT blocks
were sent to OHSU’s Histology Shared Resource where
blocks were thawed and re-embedded in paraffin, maintaining tissue orientation. Hematoxylin and eosin (H&E)
as well as immunohistochemistry (IHC) staining was
performed on serial 4 μm section from each tissue block.
IHC staining was completed with an EGFR antibody (1:
300, EP38Y, ab52894, AbCam, Cambridge, MA) targeted
to a different epitope of EGFR to prevent steric hindrance with pre-existing labeling from Cetuximab. A
Zeiss AxioScan.Z1 (Carl Zeiss Microscopy GmbH, Jena,
Germany) was used to collect bright field images of all
IHC and H&E-stained slides at 10x magnification. The
automatic tissue recognition feature in the ZEN software
(Zeiss) was used to detect ROIs of IHC and H&E slides.
Six field of views were used to set the focus map prior to
image scanning and tiling.
Statistical analysis

As previously described, statistical analysis was performed using MatLab [27]. In brief, receiver operator
characteristic (ROC) curves, using a two-by-two decision
matrix defining true positive, true negative, false positive,
and false negative, were applied to the calculated DDSI
maps to assess tumor-to-normal tissue diagnostic performance. ROC curves and corresponding area under
the curve (AUC) measurements were calculated on a
pixel-by-pixel basis with individual pixel values for each
tissue type used as the response variable input. A threshold variable was generated with a linearly increasing
value from the minimum to maximum pixel intensity
value with a number of values 100 times less than the
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total number of pixel values. The threshold variable was
then used to generate the true positive rate (TPR, percentage of tumor pixels greater than the threshold) and
false positive rate (FPR, percentage of normal pixels
greater than the threshold), ROC curves and corresponding AUC values were generated by plotting these
values at each threshold value. Significant differences between blocking conditions and washing times were evaluated using a one-way analysis of variance (ANOVA)
with Tukeys Multiple Comparison test. The α value was
set to 0.05 for all ANOVA. All ANOVA was performed
using GraphPad Prism (La Jolla, CA).

Results
Shortening DDSI blocking conditions

Blocking prior to staining with the targeted and untargeted antibody cocktail has been utilized in our DDSI
protocol to decrease non-specific binding in a similar fashion to conventional immunofluorescence staining on tissue sections or cells. Herein, varied percentages of BSA
and blocking times were compared to our previously utilized 2% BSA blocking for 10 min to determine if the overall DDSI protocol could be shortened. To permit
equivalent non-specific protein accumulation on the tissue, 5% or 10% BSA blocking conditions were tested with
shorter incubation times where 1 or 2 min were utilized
(n = 6 tumor samples per condition). Cell lines with varied
EGFR expression in vitro and grown as xenografts were
used as model systems for this work, where the high EGFR
expressing A431 cell line was compared to the mid-level
expressing AsPC-1 cell line and the minimally EGFR expressing 9L cell line (Fig. 1). Minimal difference in DDSI
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signal intensity or ROC AUC were observed in the highly
EGFR expressing A431 tumors (Fig. 2) or the mid-level
EGFR expressing AsPC-1 tumors (Fig. 3) when our previous 5 min washing condition was used with any of the
tested blocking conditions. To further examine the need
for a pre-stain blocking step, DDSI without any BSA
blocking was also tested in both the A431 and AsPC-1 tumors. While DDSI without any blocking in the highly
EGFR overexpressing A431 tumors showed robust DDSI
ROC AUC, the lower EGFR expressing AsPC-1 tumors
without blocking showed similar results to all other tested
blocking conditions (Figs. 2b and 3b). Comparison of
ROC AUC for the tested blocking conditions for A431
and AsPC-1 tumors showed no statistical difference (all p
values > 0.05).
The DDSI protocol was also evaluated in the EGFR
negative 9L cell line using the 10% BSA and 5% BSA for
2 min blocking conditions compared to DDSI without a
blocking step. Notably, all tumor and adipose tissue
showed uptake of the targeted and untargeted antibody
stains (Fig. 4a). However, this non-specific uptake was
largely corrected using the ratiometric DDSI protocol.
Histograms of pixel intensities showed greater uptake in
the benign adipose tissue as compared to the 9L tumor
tissue (Fig. 4b). ROC AUC was decreased for DDSI as
compared to the targeted and untargeted stains, which
was the expected result given the low EGFR expression
of the 9L xenografts (Fig. 4c). However, little difference
in ROC AUC for DDSI was seen between the three
tested blocking conditions. Interestingly, the DDSI pixel
intensity histograms showed more complete overlap
when using the 5% or 10% BSA blocking conditions as

Fig. 1 Flow Cytometry Quantification of EGFR status in vitro & IHC validation of EGFR receptor expression ex vivo in the A431, AsPC-1 & 9L cell
lines. a Flow cytometry-based analysis for the A431, AsPC-1 and 9L cell lines was completed for n = 3 samples per cell line to quantify EGFR
receptor expression. b Serial sections of representative resected specimens from each xenograft type (A431, AsPC-1 and 9L) were stained with
gold standard H&E and IHC to validate EGFR expression in tissue
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Fig. 2 DDSI performance under varying blocking conditions in high EGFR-expressing A431 xenografts. a Groups of A431 tumors were subject to
varied blocking conditions (2% BSA for 10 min, 5% BSA for 1 min, 5% BSA for 2 min, 10% BSA for 1 min, 10% BSA for 2 min and no blocking) to
identify the shortest blocking and corresponding washing times that maintained a robust benign and malignant tissue differentiation. All DDSI
images are optimally scaled at right (0–10 A.U.) and are representative of n = 6 tumor and adipose tissue replicates. b The DDSI tumor-to-adipose
(T/A) receiver operator characteristic (ROC) curve area under the curve (AUC) values calculated after the varied blocking conditions over washing
times were plotted to compare the quantified results

Shortening DDSI washing conditions

analysis, which showed a similar trend in DDSI ROC
AUC values with a generally increased AUC over the 5
min washing period for all tested blocking conditions
(Figs. 2b and 3b). Thus, a total washing time of 5 min
was maintained in the optimized DDSI protocol for accurate tissue differentiation.

Standard DDSI washing conditions were previously set
to a 5 min incubation in PBS containing Tween 20
followed by imaging. In an effort to further shorten the
staining protocol, DDSI contrast following each minute
of washing was evaluated in the highly EGFR expressing
A431 and mid-level EGFR expressing AsPC-1 tumors
(n = 6 tumor samples per condition). Comparison of
ROC AUC for the tested washing conditions for A431
and AsPC-1 tumors showed no statistical difference (all
p values > 0.05). However, DDSI contrast generally improved throughout the 5 min washing period, regardless
of the blocking protocol used, particularly for the midlevel EGFR expressing AsPC-1 tumors (Figs. 2a and 3a).
DDSI image data was quantified using ROC curve

Discussion
BCS remains the most common treatment for earlystage breast cancer over radical or partial mastectomy
[31]. Thus, it is imperative that surgical margins during
BCS are negative for cancer in order to decrease patient
morbidity and mortality. Current margin detection technologies have several shortcomings that have stifled
widespread clinical adoption, including: the requirement
of a pathologist within the OR, a staining time not conducive to the clinical workflow, and in some cases the
need for patient contact. With the advancement of FGS
modalities, the improvement of intraoperative margin

compared to not blocking (Fig. 4b), suggesting that a
short blocking step would provide more robust quantification of biomarker expression levels.

Fig. 3 DDSI performance under varying blocking conditions in low EGFR-expressing AsPC-1 xenografts. a Groups of AsPC-1 tumors were subject
to varied blocking conditions (2% BSA for 10 min, 5% BSA for 1 min, 5% BSA for 2 min, 10% BSA for 1 min, 10% BSA for 2 min and no blocking) to
identify the shortest blocking and corresponding washing times that maintained a robust benign and malignant tissue differentiation. All DDSI
images are optimally scaled at right (0–5 A.U.) and are representative of n = 6 tumor and adipose tissue replicates. b The DDSI tumor-to-adipose
(T/A) ROC AUC values calculated after the varied blocking conditions over washing times were plotted to compare the quantified results
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Fig. 4 DDSI under varying blocking conditions in EGFR negative 9L xenografts. a Groups of 9L rat glioma tumors were subjected to the three blocking
conditions (no blocking, 5% BSA for 2 min and 10% BSA for 2 min) to validate the robustness of optimized DDSI protocol. b Tumor and adipose tissue pixel
intensity histograms for the untargeted (top), targeted (middle) and DDSI (bottom) were used to generate c ROC curves. AUC values were calculated for that
untargeted (red), targeted (green) and DDSI (blue) ROC curves for quantitative comparison between blocking conditions

assessment has promising potential to reduce positive
margins during BCS, which can be as high as ~ 35% [5].
We have developed a fluorescent staining methodology
that can be deployed on resected specimens so that neither the contrast agents nor the FGS system require
contact with the patient, paving the way for rapid clinical
translation.
While our previously published DDSI protocol has
high sensitivity and specificity for differentiation between
benign and malignant tissues, it requires 16-min of tissue staining time [27], and thus would add substantial
OR time if used iteratively to evaluate tumor margins
during BCS. Therefore, the overall goal of this study was
to develop a tumor margin assessment modality that
could be deployed in a relevant time frame for the OR
work flow, which was set at < 10 min. The longest components of the previous DDSI protocol were the prestain blocking (10 min) and post-stain washing (5 min)
steps, where shorter blocking and washing times were
investigated herein. This effort was achieved through the
use of three tumor cell lines (A431, AsPC-1, and 9L)
with varying EGFR expression levels (Fig. 1), alongside
benign adipose tissue to ensure retention of similar
tumor-to-adipose (T/A) contrast, which is required for
successful margin assessment during BCS. Four blocking
conditions were selected including 1- or 2-min incubation with a 5% or 10% BSA solution. DDSI contrast
using each blocking condition was compared to the previously used 2% BSA blocking for 10 min. Simultaneously, the necessity for a 5 min wash was evaluated by
imaging after each minute of washing for all blocking
conditions.

The resulting DDSI ROC AUC values for each blocking condition over a cumulative 5-min of washing,
showed little variation qualitatively or quantitatively
(Figs. 2 and 3). As a result, this brought into question
the necessity of a blocking step to maintain a robust
DDSI methodology. DDSI without blocking was also
tested, and the DDSI ROC AUC was quantified over a
5-min washing period. Surprisingly, the resulting DDSI
ROC AUC values for both A431 and AsPC-1 xenografts
were similar to the other tested blocking conditions
(Figs. 2b and 3b). However, it was notable that the no
blocking condition for the highly EGFR expressing A431
tumors resulted in an overall higher uptake of untargeted probe vs. targeted probe, which led to a lower
overall calculated DDSI intensity (Fig. 2a).
The necessity of a blocking step was further evaluated
by comparing the two most promising blocking protocols (10% or 5% BSA solution incubation for 2 min) vs.
not blocking in xenografts from the 9L cell line with
minimal EGFR expression. Representative images
showed non-specific uptake of both the targeted and
untargeted probes in the tumor and benign adipose tissue, but minimal DDSI contrast between the two tissue
types as expected (Fig. 4a). The corresponding histograms and ROC curves with calculated AUC values
showed that DDSI corrected for non-specific probe uptake with DDSI values ranging from 0.65–0.69, which
were a vast improvement over the ROC AUC values for
the targeted (0.94–0.96) or untargeted (0.85–0.92)
probes alone (Fig. 4c). While the DDSI ROC AUC values
showed little difference using the 10% or 5% BSA solution incubated for 2-min vs. not blocking, the histogram
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pixel intensity values demonstrated improved receptorspecific imaging, as the histograms showed more
complete overlap for the normal, benign and tumor tissue using either blocking condition as compared to not
blocking (Fig. 4b). This suggested that utilizing a short,
high BSA percentage pre-staining blocking step will improve receptor quantification accuracy and result in a
more robust DDSI protocol.
Given these results, the 5% BSA for 2-min blocking
condition was selected as ideal for the DDSI protocol,
based on the overall trends generated from ROC curve
analysis (Figs. 2b, 3b, 4b, 4c). Although not blocking
demonstrated high AUC T/A values, lower DDSI image
intensities signified an increased uptake of the untargeted probe, suggesting that blocking with a low BSA
concentration yielded a more robust and ubiquitous
DDSI technique. Upon consideration of the washing
time necessary for sensitive and specific DDSI ROC
curves, the 5-min washing condition was maintained as
ROC AUC was generally increased for all blocking conditions for both the A431 and AsPC-1 tumor types for
all blocking conditions (Figs. 2 and 3). Thus, the total
tissue staining time for this optimized protocol was 8
min (i.e., 2 min blocking, 1 min staining, 5 min washing)
decreasing the total tissue staining time by half and fulfilling the goal of a protocol that required < 10 mins.
However, if a shorter DDSI protocol was required for
clinical work, the washing steps could be shortened
without compromising the ability to differentiate tumor
from normal tissue using the ROC AUC analysis presented herein as no statistical difference was found as
minutes of washing was increased.
The use of DDSI mitigates the need for a pathologist
in the operating room and is capable of delivering a
rapid diagnosis of the tumor margin intraoperatively
without destruction of the resected specimen. Notably,
IHC on the pre-surgical breast cancer biopsies could
provide a tailored biomarker profile for each patient, enabling personalized DDSI for improved sensitivity and
specificity. Preservation of the clinical specimen will ensure post-operative histopathology via gold standard
H&E and IHC, which can also be readily co-registered
to the corresponding DDSI maps as well as to the margin level pathology of the excised specimens. This will
facilitate future validation of the DDSI protocol and
comparison to current intraoperative margin pathological methods. In future studies, our optimized DDSI
protocol will be translated to human breast cancer specimens, enabling assessment of DDSI contrast against
multiple tissues types, where contrast against both adipose and fibroglandular tissues will be imperative for
utility to breast cancer margin detection. Since the fundamentals of DDSI rely upon the exploitation of antibody technology, the possibilities to advance this
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modality to margin detection during surgical intervention for a range of biomarkers and cancer types is a potential future direction for technology development. This
could allow for greater diagnostic and surgical intervention in a wide array of cancer types. Limitations of this
current study lie in the accuracy of the animal model
used since implanted xenografts are homogeneous compared to human cancers. Thus, for full validation, our
optimized DDSI protocol warrants translation to ex vivo
human specimens for complete validation and testing.

Conclusions
In summary, the DDSI staining methodology allows for
quantitative differentiation between normal, benign and
malignant tissues with high diagnostic performance
while requiring only 8 min of total tissue processing
time. The DDSI methodology possesses several advantages over current tumor margin detection technologies
such as touch prep-cytology and FSA, including wide
field visualization of the entire tissue specimen with high
resolution, and generation of an accurate tumor biomarker expression map, mitigating the need for specialized personnel in the OR and allowing for follow up
histopathology in which DDSI generated images can be
easily co-registered with conventional H&E and IHC. Ultimately, such an optical imaging modality provides
strong potential for rapid intraoperative margin assessment on resected specimens in a clinically relevant time
frame, allowing for clinical translation to improve patient outcomes.
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